Carl Byrnes
Stock Analyst at Northland Capital Markets
(2.00)
# 2,718
Out of 4,670 analysts
23
Total ratings
38.46%
Success rate
7.18%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TLSI TriSalus Life Sciences | Initiates: Outperform | $13 | $4.53 | +175.94% | 1 | Oct 25, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $11 → $13 | $10.00 | +25.00% | 3 | Oct 3, 2024 | |
| ONCT Oncternal Therapeutics | Downgrades: Market Perform | $2 | $1.14 | +75.44% | 1 | Sep 12, 2024 | |
| MDAI Spectral AI | Initiates: Outperform | $6 | $1.19 | +404.20% | 1 | Aug 12, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $26 → $28 | $26.01 | +7.65% | 1 | Aug 9, 2024 | |
| COCH Envoy Medical | Initiates: Outperform | n/a | $2.18 | - | 1 | Dec 21, 2023 | |
| AMRN Amarin Corporation | Maintains: Market Perform | $2 → $1.25 | $0.55 | +127.85% | 1 | Jul 19, 2023 | |
| CDIO Cardio Diagnostics Holdings | Initiates: Outperform | $8 | $0.27 | +2,914.32% | 1 | May 22, 2023 | |
| VTVT vTv Therapeutics | Maintains: Outperform | $60 → $80 | $14.18 | +464.17% | 4 | Aug 17, 2022 | |
| MDXG MiMedx Group | Initiates: Outperform | $23 | $9.20 | +150.00% | 3 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $30 → $24 | $2.52 | +852.38% | 4 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $2,000 | $1.63 | +122,599.39% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.07 | - | 1 | Sep 27, 2017 |
TriSalus Life Sciences
Oct 25, 2024
Initiates: Outperform
Price Target: $13
Current: $4.53
Upside: +175.94%
BrainsWay
Oct 3, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $10.00
Upside: +25.00%
Oncternal Therapeutics
Sep 12, 2024
Downgrades: Market Perform
Price Target: $2
Current: $1.14
Upside: +75.44%
Spectral AI
Aug 12, 2024
Initiates: Outperform
Price Target: $6
Current: $1.19
Upside: +404.20%
BioLife Solutions
Aug 9, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $26.01
Upside: +7.65%
Envoy Medical
Dec 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $2.18
Upside: -
Amarin Corporation
Jul 19, 2023
Maintains: Market Perform
Price Target: $2 → $1.25
Current: $0.55
Upside: +127.85%
Cardio Diagnostics Holdings
May 22, 2023
Initiates: Outperform
Price Target: $8
Current: $0.27
Upside: +2,914.32%
vTv Therapeutics
Aug 17, 2022
Maintains: Outperform
Price Target: $60 → $80
Current: $14.18
Upside: +464.17%
MiMedx Group
Jul 26, 2021
Initiates: Outperform
Price Target: $23
Current: $9.20
Upside: +150.00%
May 5, 2021
Maintains: Market Perform
Price Target: $30 → $24
Current: $2.52
Upside: +852.38%
Oct 22, 2018
Initiates: Outperform
Price Target: $2,000
Current: $1.63
Upside: +122,599.39%
Sep 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.07
Upside: -